Heterocyclic kinase inhibitors

A compound of formula I-H:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 is hydrogen;
• n is an integer from 0 to 2;
• L1 is a bond;
• R3 is hydrogen;
• R4 and R5 are taken together to form a fused phenyl ring, wherein the phenyl ring is unsubstituted;
• z is 1, 2, or 3;
• each of R6 is independently hydrogen, halogen, —CN, —OR10, —S(O)nR11, —NR12R13, —C(O)R14, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each of R7 and R8 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocyclyalkyl, or R7 and R8 taken together form a cycloalkyl, heterocycloalkyl or aryl ring;
• R9 is aryl or —NR12R13, wherein R12 and R13 are taken together to form a 5, 6, 7, or 8 membered ring, wherein the 5, 6, 7, or 8 membered ring contains 0, 1, 2 or 3 ring heteroatoms selected from N, S, or O in addition to the nitrogen atom of —NR12R13;
• and further wherein the 5, 6, 7, or 8 membered ring is optionally substituted;
• each R10 is independently hydrogen, —C(O)R15, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each R11 is independently —NR16R17, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each R12 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each R13 is independently hydrogen, —S(O)nR18, —C(O)R19, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• or R12 and R13 are taken together to form a 5, 6, 7, or 8 membered ring, wherein the 5, 6, 7, or 8 membered ring contains 0, 1, 2 or 3 ring heteroatoms selected from N, S, or O in addition to the nitrogen atom of —NR12R13;
• and further wherein the 5, 6, 7, or 8 membered ring is optionally substituted;
• each R14 is independently —NR20R21, hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each R15 is independently —NR22R23, hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each of R16 and R17 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• or R16 and R17 are taken together to form a 5, 6, 7, or 8 membered ring, wherein the 5, 6, 7, or 8 membered ring contains 0, 1, 2 or 3 ring heteroatoms selected from N, S, or O in addition to the nitrogen atom of —NR16R17;
• and further wherein the 5, 6, 7, or 8 membered ring is optionally substituted;
• each R18 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each R19 is independently —NR24R25, hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
• each of R20 and R21 is independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R20 and R21 are taken together to form a 5, 6, 7, or 8 membered ring, wherein the 5, 6, 7, or 8 membered ring contains 0, 1, 2 or 3 ring heteroatoms selected from N, S, or O in addition to the nitrogen atom of —NR20R21;
• and further wherein the 5, 6, 7, or 8 membered ring is optionally substituted;
• each R22 and R23 are independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R22 and R23 are taken together to form a 5, 6, 7, or 8 membered ring, wherein the 5, 6, 7, or 8 membered ring contains 0, 1, 2 or 3 ring heteroatoms selected from N, S, or O in addition to the nitrogen atom of —NR22R23;
• and further wherein the 5, 6, 7, or 8 membered ring is optionally substituted;
• each R24 and R25 are independently hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R24 and R25 are taken together to form a 5, 6, 7, or 8 membered ring, wherein the 5, 6, 7, or 8 membered ring contains 0, 1, 2 or 3 ring heteroatoms selected from N, S, or O in addition to the nitrogen atom of —NR24 R25;
• and further wherein the 5, 6, 7, or 8 membered ring is optionally substituted;
• and
• W is CR6 or N.